Table 1.
Demographic and clinical parameters, as well as concentration of salivary and serum αSyn and 3-nitrotyrosine proteins, in patients with IPD and control subjects.
| IPD (n = 45) | Control (n = 30) | P | |
|---|---|---|---|
| Demographic and clinical parameters | |||
| Age (years) | 61.4 ± 18.5 | 59.6 ± 11 | NS |
| Gender, male n (%) | 27(60) | 12 (40) | NS |
| Body mass index | 23.1 ± 2 | 24.8 ± 2.5 | NS |
| Education (years) | 17.8 ± 2.1 | 17.3 ± 2.2 | NS |
| Levodopa equivalent dose (mg per day) | 595.9 ± 650 | ||
| Disease duration (years) | 9.9 ± 6.8 | ||
| Age at IPD onset (years) | 57.9 ± 13.1 | ||
| Hoehn-Yahr stage | 2.1 ± 0.8 | ||
| Modified Schwab-England | 86 ± 25 | ||
| MDS-UPDRS part III (on) | 24 ± 12 | ||
| Total MDS-UPDRS (I-III) (on) | 37.2 ± 20 | ||
| MDS-UPDRS part IV | 1.2 ± 2.4 | ||
| Native αSyn concentration (pg/mL) | |||
| Saliva | 361.9 ± 89 | 372.1 ± 91 | NS |
| Serum | 244,789 ± 114,017 | 297,783 ± 110,992 | NS |
| Saliva/serum αSyn ratio | 0.0015 ± 0.001 | 0.0013 ± 0.001 | NS |
| 3-Nitrotyrosine proteins concentration (µg/mL) | |||
| Saliva | 0.35 ± 0.28 | 0.33 ± 0.27 | NS |
| Serum | 1.52 ± 0.87 | 1.94 ± 1.23 | NS |
| Saliva/serum 3-NT-proteins ratio | 0.27 ± 0.25 | 0.21 ± 0.15 | NS |
Mean ± SD. Statistical comparisons were carried out with the χ2 test (dichotomous variables) or the Student’s t-test (quantitative variables). Abbrev.: IPD, idiopathic Parkinson’s disease; NS, nonsignificant; UPDRS, Unified Parkinson’s Disease Rating Scale; P, probability; αSyn, α-synuclein; 3-NT-proteins, 3-nitrotyrosine proteins.